Search > Age-Related Macular Degeneration
237 Participants NeededMy employer runs this trial

Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD

Recruiting at 2 trial locations
UQ
PM
Overseen ByPayton Marvel, M.S
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Ocugen
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is a Phase 3 multicenter, randomized, controlled, assessor blinded, adaptive study in which subjects will be randomized in a 2:1(OCU410: control) ratio to treatment arm or control arm

Who Is on the Research Team?

MG

Mohamed Genead, MD

Principal Investigator

Ocugen., Inc.

JH

Jennifer Henrick

Principal Investigator

Ocugen., Inc

Are You a Good Fit for This Trial?

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: OCU410Experimental Treatment1 Intervention
Group II: Untreated Control ArmActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Ocugen

Lead Sponsor

Trials
12
Recruited
1,100+

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.